Phosphino sulphonates, a type of P<sup>III</sup>-anhydride and their isomerisation into phosphinoyl sulphinates: a novel rearrangement in phosphorus–sulphur chemistry
The imidazolides (1) react smoothly with RSO3H to afford a novel class of trico-ordinate phosphorus anhydride, the phosphinosulphonates (2); under sutable structure circumstances the compounds (2) undergo a noveltype of rearrangement, (2)→(6), which provides the first example of a phosphinoylsulphinate structure (6).
Thiocyanation of dialkyl phosphites and their structural analogues by thiocyanogen (SCN)2: Mechanism and stereochemistry
作者:A. łopusiński、L. łuczak、J. Michalski
DOI:10.1016/0040-4020(82)80210-x
日期:1982.1
O, S) has been reinvestigated. The reaction wa shown to be highly stereospecific and proceeds with the retention of configuration at P via the thiocyanidate >P(O)SCN structure. The thiocyanidates rearrange into the isothiocyanidates >P(O)NCS with a rate of depending on structure of substrates and reaction conditions. The thiocyanation reaction of dialykl phosphite and their structural analogues offers
Krawiecka, Bozena; Wojna-Tadeusiak, Elzbieta, Journal of the Chemical Society. Perkin transactions I, 1991, # 1, p. 229 - 237
作者:Krawiecka, Bozena、Wojna-Tadeusiak, Elzbieta
DOI:——
日期:——
2-Arylbenzo[<i>d</i>]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy
作者:Arran Babbs、Adam Berg、Maria Chatzopoulou、Kay E. Davies、Stephen G. Davies、Benjamin Edwards、David J. Elsey、Enrico Emer、Simon Guiraud、Shawn Harriman、Cristina Lecci、Lee Moir、David Peters、Neil Robinson、Jessica A. Rowley、Angela J. Russell、Sarah E. Squire、Jonathon M. Tinsley、Francis X. Wilson、Graham M. Wynne
DOI:10.1021/acs.jmedchem.0c00807
日期:2020.7.23
Utrophin modulation is a promising therapeutic strategy for Duchenne muscular dystrophy (DMD), which should be applicable to all patient populations. Following on from ezutromid, the first-generation utrophin modulator, we describe the development of a second generation of utrophin modulators, based on the bioisosteric replacement of the sulfone group with a phosphinate ester and substitution of the metabolically labile naphthalene with a haloaryl substituent. The improved physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties, further reflected in the enhanced pharmacokinetic profile of the most advanced compounds, 30 and 27, led to significantly better in vivo exposure compared to ezutromid and alleviation of the dystrophic phenotype in mdx mice. While 30 was found to have dose-limiting hepatotoxicity, 27 and its enantiomers exhibited limited off-target effects, resulting in a safe profile and highlighting their potential utility as next-generation utrophin modulators suitable for progression toward a future DMD therapy.